Dr. Reddy's Laboratories Limited — research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Dr. Reddy's Laboratories Limited, explained in plain English.

• ▪Dr. Reddy's Laboratories Limited is tracked in the Pharma & Healthcare sector of our NSE large-cap universe.
• ▪Reported fundamentals show return on equity of 8.84%, a net margin of 10.0%, debt to equity of 18.61.
• ▪Our transparent MaxGrade checklist scores it F (23/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 23.53% with a maximum drawdown of -17.45% and a beta of 0.46 against NIFTY 50.
• ▪Recent coverage: Last line of defence! How 7 Nifty stocks survived the market’s two-month bloodbath
• ▪Recent coverage: Top 5 Sumeet Bagadia's breakout stocks: Gland Pharma, Astra Micro, Meesho, Westlife, Ujjivan | Target price, stop-loss
• ▪Recent coverage: Top stocks to buy for short term: M&M, Engineers India and 1 other by Master Capital Services - Target price, stop loss

Figures from the current session. Market open.